Efficacy hierarchy and absolute survival benefit of first-line immunotherapy in advanced gastric cancer: a meta-analysis and pooled survival analysis
BackgroundWhile immune checkpoint inhibitors (ICIs) have revolutionized first-line treatment for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma, outcomes across phase III trials remained heterogeneous. This study aimed to determine…